ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)

Data ReadoutpositiveantimiR-23bPositive

AI Analysis

Summary

ARTHEx Biotech published preclinical data demonstrating that its antimiR-23b candidate, delivered systemically via the BOOST-ON platform, crosses the blood-brain barrier and improves behavioral alterations in a DM1 model. The positive preclinical findings highlight potential to address CNS manifestations of myotonic dystrophy type 1.

Clinical Trial Data

Phase

preclinical

Primary Endpoint

Met

Outcome Details

Systemic delivery of antimiR-23b reached the brain, corrected disease biology, and improved behavior in preclinical model of DM1

Importance:4/10

Sentiment:

0.75

preclinical dataCNS manifestationmyotonic dystrophyantimiR therapeuticBOOST-ON platform

Related Companies

$BNN.DE $TRAX

Read the original article

Published by PR Newswire Clinical Trials on July 23, 2026 7:00 AM

Read Original